IFNG and neoplasm: Recent studies have shown that targeting TBK1 can reduce the sensitivity of tumor cells to effector cytokines (such as TNF-α and IFN-γ), promote tumor cell apoptosis, and reverse tumor resistance to immunotherapy (85).